Compare Heron Therapeutics Inc (HRTX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard High Dividend Yield ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Vanguard High Dividend Yield ETF trades at $158.5 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 1361.4× Heron Therapeutics Inc's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| HRTX | VYM | |
|---|---|---|
Market Cap | $74.04M | $100.80B |
Volume | 3,668,095 | 993,696 |
Sector | Health | — |
52-Week High | $1.49 | $167.03 |
52-Week Low | $0.27 | $137.47 |
Typical Hold Time | 35 Days | 138 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
VYM trades at $157.45, down 0.58% on the day, with a bearish technical signal from moving averages while oscillators remain neutral. The ETF's 2.42% yield provides consistent income, though recent articles highlight performance comparisons with peers like SCHD and IDV. Support and resistance levels cluster tightly around $157-158, indicating potential for near-term price consolidation.
The outlook remains cautious as VYM faces competitive pressure from higher-yielding alternatives and concerns about dividend sustainability in its holdings. While diversification and low costs are strengths, investors should weigh the trade-offs between yield consistency and total return potential in the current market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
